[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Halozyme Therapeutics insider Nicole LaBrosse executed option exercises and share sales under a Rule 10b5-1 plan on 09/10/2025. The reporting shows exercise of options to purchase 11,271 shares at $12.07 and 1,135 shares at $12.49, and brokered sales of 6,760 and 13,240 shares at weighted average prices in the $74.56–$76.30 range. After these transactions the reporting person beneficially owned 24,306 shares of common stock directly. The Form 4 discloses the trades were effected pursuant to a 10b5-1 trading plan adopted on June 11, 2025, and includes vesting histories for the reported options.

Positive

• Transactions were executed under a Rule 10b5-1 trading plan, indicating pre-arranged, compliant insider trading
• Option grants and vesting schedules for the exercised options are disclosed (Feb 22, 2017 and Aug 1, 2017)

Negative

• Reporting person’s direct holdings decreased to 24,306 shares after the exercises and sales, indicating a material reduction in ownership
• 20,000 shares sold (6,760 and 13,240) at weighted average prices in the $74.56–$76.30 range, representing realized insider sales

Insights

Financial Analyst

TL;DR: Insider exercised options and sold shares under a 10b5-1 plan, reducing direct holdings materially.

The filing documents option exercises totaling 12,406 shares exercisable at $12.07 and $12.49 and subsequent market sales of 20,000 shares (6,760 and 13,240) at weighted averages between $74.56 and $76.30. The transactions were executed by a broker under a Rule 10b5-1 plan adopted on June 11, 2025. From an investor-impact perspective, these are non-derivative, routine insider transactions that reduce the reporting person’s direct stake to 24,306 shares; they are informative about insider liquidity but do not by themselves reveal company operational changes.

Corporate Governance Expert

TL;DR: Trades followed a pre-established 10b5-1 plan, which supports compliance though results in a notable drop in direct ownership.

The Form 4 clearly states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted June 11, 2025, indicating an affirmative defense to insider trading claims. The filing also documents the original grant and vesting schedules for the options (grants dated Feb 22, 2017 and Aug 1, 2017). Governance-wise, the transparency and plan disclosure align with best practices; however, the substantial reduction in direct holdings to 24,306 shares may be of interest to shareholders assessing insider alignment with long-term interests.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaBrosse Nicole

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2025		M(1)		11,271	A	$12.07	43,171	D
Common Stock	09/10/2025		M(1)		1,135	A	$12.49	44,306	D
Common Stock	09/10/2025		S(1)		6,760	D	$75.291(2)	37,546	D
Common Stock	09/10/2025		S(1)		13,240	D	$75.929(3)	24,306	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$12.07	09/10/2025		M(1)			11,271	(4)	02/22/2027	Common Stock	11,271	$0	0	D
Option to Purchase Common Stock	$12.49	09/10/2025		M(1)			1,135	(5)	08/01/2027	Common Stock	1,135	$0	812	D

Explanation of Responses:

1. The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

2. Represents a weighted average sales price per share. These shares were sold at prices ranging from $74.56 to $75.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. These shares were sold at prices ranging from $75.56 to $76.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

5. This option was granted on August 1, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

	/s/ James R. Oehler, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did HALO (Halozyme) report on the Form 4?

Nicole LaBrosse exercised options for 11,271 and 1,135 shares and sold 6,760 and 13,240 shares on 09/10/2025.

Were the trades executed under a trading plan for HALO insider Nicole LaBrosse?

Yes. The Form 4 states the trades were effected by a broker pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2025.

What prices were the HALO shares sold for in the reported transactions?

Sales were at weighted average prices ranging from $74.56 to $75.55 for one block and $75.56 to $76.30 for the other; specific weighted averages reported in the Form 4 are $75.291 and $75.929.

How many HALO shares does the reporting person own after the transactions?

Following the reported transactions the reporting person beneficially owned 24,306 shares of common stock (directly).

When were the exercised options originally granted and how did they vest?

One option was granted on 02/22/2017 and the other on 08/01/2017; both vested one-fourth on the first anniversary and then monthly thereafter (1/48th).